Compare Amphastar Pharmaceuticals Inc (AMPH) vs ConocoPhillips (COP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs ConocoPhillips — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while ConocoPhillips trades at $110.3 (market cap $132.84B). The key difference: ConocoPhillips is far larger — about 160.8× Amphastar Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 3.08% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | COP | |
|---|---|---|
Market Cap | $826.08M | $132.84B |
Sector | Health | Energy |
52-Week High | $30.81 | $133.80 |
52-Week Low | $16.87 | $85.66 |
Enterprise Value | $1.22B | $149.81B |
Dividend Yield | — | 3.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
ConocoPhillips (COP) trades at $109.04, up 0.94% with a bullish technical signal despite mixed moving averages. The company maintains solid fundamentals with $58.94B revenue, 12.58% net margin, and consistent cash flow generation. Recent earnings show beats in Q3 2025 and Q1 2026, while analysts project strong Q2 2026 EPS of $2.85. The stock offers a dividend yield with recent $0.84 payout, supported by 74.51% buy ratings from coverage analysts.
COP presents a compelling value opportunity with P/E of 18.48 and EV/EBITDA of 6.08 below sector averages. The consensus price target of $137.14 implies 26% upside potential. Key risks include oil price volatility, geopolitical tensions affecting Middle East supply, and declining profit margins from 23.79% in 2022 to 13.55% in 2025. The upcoming Q2 earnings on August 6, 2026, will be crucial for validating growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →
